Skip to main content
Premium Trial:

Request an Annual Quote

GC Biotech to Distribute CryoXtract Products in Benelux, Germany

NEW YORK (GenomeWeb News) – CryoXtract Instruments said this week that it has entered into an exclusive distribution deal with GC Biotech for the distribution of CryoXtract's automation solutions for preserving and optimizing frozen biological samples in the Benelux countries and Germany.

The deal is the first international partnership by CryoXtract since it named John McCarthy its CEO last month, it said, adding that the Benelux region and Germany is one of "the most important and progressive European markets for human genetics research and development," with a need for "sophisticated biobanking requirements."

The agreement provides CryoXtract "with a broad and experienced foundation of marketing, engineering support, and logistics services throughout this important European market," McCarthy said in a statement. "GC biotech represents the first of what we expect will be a network of strong international partners that can help accelerate introduction and adoption of our high-value products among the industry's thought leaders."

Financial and other terms of the deal were not disclosed.

CryoXtract, based in Woburn, Mass., develops automation solutions for retrieving multiple frozen samples from a single frozen biosample "without exposing the source sample to the deleterious biological impact from freeze/thaw cycling," it said. The firm has developed a technology platform for aliquotting biosamples while preserving the minus-80 degree Celsius environment.

GC biotech is based Alphen aan den Rijn, The Netherlands and distributes specialized life science products.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.